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Abbreviations used in this paper: 
ESS: Epworth Sleepiness Scale 
BCAA: Branched chain amino acid 
LES: Late evening snack 
LC: Liver cirrhosis 
QOL: Quality of life 
WBC: White blood cells  
RBC: Red blood cells 
Plt: Platelets 
PT: prothrombin time 
BUN: blood urea nitrogen 
Cr: creatinine 
AST: Aspartate aminotransferase 
ALT: Alanine aminotransferase 
γ-GTP: γ-glutamyltranspeptidase 
ALP: Alkaline phosphatase 
TB: Total bilirubin 
TP: Total protein 
Alb: Albumin 
TC: Total cholesterol 
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ChE: Cholinesterase 
TG: Triglyceride 
FPG: Fasting blood glucose 
NH3: Ammonia 
BTR: BCAA/tyrosine ratio 
MHE: minimal hepatic encephalopathy 
PBC: primary biliary cirrhosis 
TACE: Trans-arterial chemoembolization 
 
 





 Ichikawa T., et. al., Page. 4  
ABSTRACT 
Aim; Sleep is closely related to physical and mental health. Sleep disturbance is reported to the 
patient without encephalopathy. We made an original symptom evaluation question item, and 
examined the relation among cirrhotic symptoms, laboratory data and sleep disturbance. .Next, we 
examined the influence that a BCAA supplement gave the sleep disturbance of cirrhotic patients.  
Methods; We investigated a total of 21 patients at Nagasaki University Hospital, including 9 men 
and 11 women from January to June 2009. We constructed questionnaire items for evaluation of 
cirrhotic symptom. The items, as major symptoms of cirrhotic patients, are follows; hands tremor, 
appetite loss, muscle cramp of foot, fatigue, decreased strength, become anxious, abdominal 
fullness, abdominal pain and feel of low energy. We used the Epworth Sleepiness scale (ESS) for 
evaluation of daytime hyper-somnolence. Energy supplementation of BCAA snack was performed 
as late evening snack (LES). All patients were assessed at entry, 4 weeks and 8 weeks.  
Result; It was presented that BCAA snack, was taken orally as LES, improved the ESS for cirrhotic 
patients without encephalopathy. This beneficial result was recognized in short term, 4 weeks after 
beginning of treatment. This study demonstrates availability of BCAA supplementation for cirrhotic 
patients with sleep disturbance. However, the cirrhotic symptom related score was positively 
relation with Child-Pugh score at entry, we were not able to find the item that related to ESS. 
Conclusion; BCAA snack is the useful drug for cirrhotic patients whom do not have overt 
encephalopathy but suffered sleep disturbance.  
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INTRODUCTION 
 The patients with liver cirrhosis (LC) has a widely spread symptom. A few cirrhotic 
patients has sleep disturbance (1). In recent years, it has been reported that sleep is closely related to 
physical and mental health (2. 3). Sleep disturbance is one of the symptoms of overt hepatic 
encephalopathy (4), but is reported to the patient without encephalopathy (1). In previous report (1), 
the questionnaire indicated the elevated number (47.7%) of cirrhotic patient who complained of 
unsatisfactory sleep compared with healthy control (4.5%). Additionally, global sleep quality was 
significantly lower in the primary biliary cirrhosis group (5) and the non-alcoholic fatty liver 
disease group (6) compared to control. In Japan, the overall prevalence of insomnia during the 
preceding month was 21.4% among the Japanese general population (7). In this study, we examined 
the actual circumstance of the sleep disturbance in Japanese cirrhotic patients.  
 The relation among the sleep disturbance and a variegated cirrhotic symptom are not yet 
clear. Previous reports indicated that sleep disturbance is not related to liver function (1. 8). It is 
reported that fatigue in non-alcoholic fatty liver disease is significant and associates with excessive 
daytime sleepiness but not insulin resistance (6). Because of emergence of sleep disturbance in 
cirrhotic patient without encephalopathy, the relation between the sleep disturbance and cirrhotic 
symptom exclude encephalopathy should be examined. In this study, we made an original symptom 
evaluation question item, and examined the relation between sleep disturbance and other cirrhotic 
symptoms.  
The energy balance of LC was characterized as protein-energy malnutrition (PEM), 
 Ichikawa T., et. al., Page. 6  
involved disorder of glycolysis, decline of glycogenosis, negative nitrogen balance and 
hyper-lipolysis (9. 10. 11). PEM carries a high risk of morbidity and mortality by increasing the risk 
of life-threatening complications, which in turn reduce quality of life (QOL), independent of liver 
function (12. 13). Recently, branched-chain amino acids (BCAA) supplementation in patients with 
liver disease is paid attention. The administration of BCAA has been shown to correct malnutrition 
associated with LC in both animal and human studies (14. 15) Additionally, it has been reported that 
long-term nutritional BCAA supplementation is useful to prevent prognosis hepatic failure and to 
improve surrogate markers in advanced LC (15. 16. 17). It is described that BCAA supplement is 
effective in down-regulating protein metabolism in LC, improving nitrogen balance, and finally 
resulting in better clinical outcomes (15. 18. 19). It is also speculated that the mechanisms for 
beneficial effects of BCAA might be mediated by their stimulating activity on hepatocyte growth 
factor, favoring liver regeneration (20). Previously, we indicate that a BCAA supplement taken 
orally as a late evening snack prevents suppression of liver function by TACE in patients with LC 
complicated with HCC during the 2-week period after TACE (21). However, BCAA is the useful 
drug for hepatic malnutrition and encephalopathy (4), the influence of BCAA given to sleep 
disturbance has not been reported. Therefore, we examined the influence that a BCAA supplement 
gave the sleep disturbance of cirrhotic patients. 
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PATIENTS AND METHODS 
 
Patients 
We investigated a total of 21 patients at Nagasaki University Hospital, including 9 men and 
11 women from January to June 2009 (table 1). All patients were LC without hepatocellular 
carcinoma, history of hepatic encephalopathy, chronic renal failure, internal use of BCAA drug, 
refill of the albumin preparation and alcohol drinking. The diagnosis of hepatocellular carcinoma 
was based on findings on contrast enhancement computed tomography scan and magnetic 
resonance imaging. Hepatic encephalopathy was diagnosed by clinical findings. All patients had 
diagnosed LC by laboratory data and imaging findings at entry of study and not prescribed BCAA 
supplement before this study. After balancing of the both groups for sex, age, Child-Pugh score, 
cirrhotic symptom related score and albumin level, patients were randomized into two group, 
BCAA enriched supplementation group and control group. All patients in both groups did not 
suffered overt hepatic encephalopathy and HCC during observation period. We had followed all 
patients in our hospital.  
 
Laboratory measurements 
Laboratory data, anthropometric measurements and survey by questionnaire were 
performed at the day of entry (at entry), 4 weeks later (4 weeks) and 8 weeks later (8 weeks). Body 
mass index, BMI, was calculated as weight (kg) divided by the square of height (m). Laboratory 
measurements were as follow; white blood cell (WBC), red blood cell (RBC), platelet (Plt), 
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prothrombin time (PT), blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), γ-glutamyltranspeptidase (γ-GTP), alkaline phosphatase 
(ALP), total bilirubin (TB), total protein (TP), albumin (Alb), total cholesterol (TC), cholinesterase 
(ChE), triglyceride (TG), fasting blood glucose (FPG), ammonia (NH3) and BCAA/tyrosine ratio 
(BTR).  
 
Survey by questionnaire 
 We constructed questionnaire items for evaluation of cirrhotic symptom. The items, as 
major symptoms of cirrhotic patients, are follows; hands tremor, appetite loss, muscle cramp of 
foot, fatigue, decreased strength, become anxious, abdominal fullness, abdominal pain and feel of 
low energy. For each items, we calculated an “impact factor”, the product of proportion of patients 
identified the item as a problem (frequency), and the mean importance attributed to that item. The 
impact factor for each item could range from 0 to 6. We investigate total of impact factors (cirrhotic 
symptom related score). Next, we used the Epworth Sleepiness scale (ESS) (22) for evaluation of 
daytime hyper-somnolence. ESS score rang is from 0 to 24, a score of 10 or more being indicative 
of significant of daytime hyper-somnolence. All patients were assessed by cirrhotic symptom 
related score and ESS at entry, 4 weeks and 8 weeks.  
 
Protocol for intake of branched chain amino acids enriched snack 
We used a branched chain amino acids enriched snack (Aminoleban EN, Otsuka 
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Pharmaceutical Co., Tokyo) for supplementation of the LC patients. The treated patients were 
started once a day of orally 50g as BCAA snack at 22:00 of the one day at entry and continued after 
the entry for 8 weeks. Aminoleban EN was snack, contained 13.5g protein, high levels of BCAA 
and low levels of the other amino acids, as Fischer ration 38, and 210 kcal of energy per 50g on one 
pack. Energy supplementation of BCAA snack was performed as late evening snack (LES) (21). 
Patients in the BCAA group carried on intake of BCAA snack afteryears. Beside, patients in the 
control group did not take BCAA snack. Patients were instructed to maintain a diet containing 
30–35 kcal and 1.2–1.3 g of protein per kilogram of ideal body weight per day. In the BCAA group, 
the patients were educated to adjust their total energy intake by subtracting 210 kcal of BCAA 
snack from the meals. In the control group, the control rice ball as late evening snack provided 210 
kcal of energy with 9 g of protein. Nutritional intake was evaluated to all patients by dietitians at 
initial period, 4 weeks after and 8 weeks after. 
 
Statistical analysis 
Data were processed on a personal computer and analyzed using StatView 5.0 (SAS 
Institute, Inc., Cary, NC).The differences of each laboratory data were analyzed by Mann-Whitney 
U test and χ-square test for number. In addition, relation with items was evaluated by coefficient of 
correlation. Values of P < 0.05 were considered statistically significant.  
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RESULTS 
  This study included 21 patients, randomized either to the BCAA group, n=12, and the 
control group, n=9. Baseline clinical characteristics were revealed the table 1. The Child– Pugh 
classification A: B: C is 6: 5: 1 and 5: 3: 1 in the BCAA and control group, respectively. Hepatitis B 
virus infection and hepatitis C virus infection in BCAA and control group are at equal rate, 
respectively. The other etiology is one of autoimmune hepatitis and one of cryptogenic in the BCAA 
group and one of primary biliary cirrhosis and one of non-alcoholic steatohepatitis in the control 
group and all other etiology patients are female. All patients were outpatient during observation 
period and not were admitted to a hospital. In the BCAA group, adverse effects of BCAA snack 
were not found. Nutritional intake was not difference among initial period, 4 weeks after and 8 
weeks after. The LES of BCAA snack were well tolerable diets and had good compliance in all 
patients of BCAA group. 
 Laboratory data at 8 weeks and variation between at entry and 8 weeks were showed in 
table 2. In 8 weeks analysis, levels of all laboratory data were equivalent between the BCAA and 
control group. In the variation between entry and 8 weeks in groups, all laboratory data were 
equivalent between the BCAA and control group. BMI at 8 weeks and variation of BMI did not 
have significant difference between both groups, too. 
 Although, laboratory data and BMI did not changed between entry and 8 weeks, cirrhotic 
symptom related score and ESS were influenced by BCAA snack (fig. 1). Cirrhotic symptom 
related score (mean±SD) is 17.12±7.76 and 16.7±10.1 at entry, 16.08±5.94 and 18.3±10.4 at 4 
 Ichikawa T., et. al., Page. 11  
weeks and 11.7±5.23 and 17.9±10.5 at 8 weeks (fig. 1A). At 8weeks, in the BCAA group, score is 
declining trend from at entry. The evaluation of differnce among entry, 4 weeks and 8 weeks 
speculated declining trend in the BCAA group (fig. 1B). “4W-entry”, “8W-entry” and “8W-4W” 
also were -1.08±7.60 and 1.667±2.96, -4.42±5.57 and -0.444±2.79, -5.50±10.3 and 1.22±4.32 in the 
BCAA and cntrol group, respectively. On the contrary, ESS is recognaized ststical siginificant by 
BCAA treatmen (fig. 1C, D). ESS (mean±SD) is 7.67±4.21 and 4.67±3.35 at entry, 5.50±3.15 and 
5.78±3.528 at 4 weeks and 4.81±2.19 and 5.78±3.27 at 8 weeks (fig. 1C). However,the value of 
ESS is not detected significal difference at indicated period in both group, The differnce among 
entry, 4 weeks and 8 weeks were caliculated (fig. 1B). “4W-entry”, “8W-entry” and “8W-4W” also 
were -2.16±3.46 and 1.11±1.364, -0.917±1.78 and -0.00±0.866, -3.08±3.66 and 1.11±1.17 in the 
BCAA and cntrol group, respectively. It was understood that a significant decrease of ESS had 
already started on the fourth week of beginning of the treatment. A significant decrease became 
more eminent on the eighth week of beginning of the treatment (fig. 1D).  
 At the last, we examined the factor that related to ESS at entry. At entry, the cirrhotic 
symptom related score was positively relation with Child-Pugh score (R=0.545), but not relation 
with ESS (fig. 2A, B). Additionally, ESS was not relation with Child-Pugh score (fig. 2C), each 
items of the cirrhotic symptom related score and laboratory data (BMI, WBC, RBC, Plt, PT, BUN, 
Cr, AST, ALT, γ-GTP, ALP, TB, TP, Alb, TC, ChE, TG, FPG, NH3 and BTR) at entry. In the 
comparison at entry and 8 weeks after, ESS has been improved only by the BCAA treatment group 
and we found only one case who increment of ESS or cirrhotic symptom related score gone 
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negative in the control group (fig. 2D).  
 There are four cases, has 10 or more score of ESS, in BCAA group. ESS at entry, 4 weeks 
and 8 weeks is 17, 7, 5 in 50 years old female suffered hepatitis B virus infection (Child-Pugh score 
(CPS) 6 and cirrhotic symptom related score (CSS) 15), 10, 6, 6 in 55 years old male suffered 
alcohol drinking (CPS 7 and CSS 30), 12, 13, 9 in 71 years old female suffered hepatitis B virus 
infection (CPS 5 and CSS 23) and 10, 5, 5 in 73 years old male suffered alcohol drinking (CPS 5 
and CSS 6). Three of four patients were diminished ESS score at 4 weeks compared with at entry, 
all patients were improved to below 10 of ESS. ESS at entry, 4 weeks, 8 weeks is 11, 13, 12 in 77 
years old male suffered hepatitis C virus infection (CPS 7 and CSS 30) in control group.  
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DISCUSSION 
In this study, it was presented that BCAA snack, was taken orally as late evening snack 
(LES), improved the ESS for cirrhotic patients without encephalopathy, recently. This beneficial 
result was recognized in short term, 4 weeks after beginning of treatment. This study demonstrates 
availability of BCAA supplementation for cirrhotic patients with sleep disturbance. However, the 
cirrhotic symptom related score was positively relation with Child-Pugh score at entry, we were 
not able to find the item that related to ESS.  
The frequency of sleep disturbance in cirrhotic patients can not be evaluated in this study, 
because we did not set the normal healthy control group. 10 or more ESS, as significant of daytime 
hyper-somnolence, is 5 cases of 21 cirrhotic patients (23.8%), and all cirrhotic patients have a 
mean ESS of 6.38 in this study. In Japanese previous report (23), it is described that a mean ESS of 
5.6 in 144 healthy control cases are lower than Parkinson disease group. In Italian study (8), it is 
reported that cirrhotic patients had a mean ESS of 6.66 (6.17 in health control), and 15.7% of them 
had a higher than 10 of ESS (12.9% in healthy controls). In primary biliary cirrhosis study (5), it is 
reported that patients had a mean ESS of 9 (5 in health control), and more than 50% of them had a 
higher than 10 of ESS (15% in healthy controls). We think that our ESS data of cirrhotic patient is 
not very different from the previous study. And, all of the patients with significant of daytime 
hyper-somnolence were improved by BCAA snack in this study.  
The mechanism of sleep disturbance in cirrhotic patient is still unclear. Thus far, it has been 
considered that sleep disturbance is the early sing of hepatic encephalopathy and symptom of 
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“minimal hepatic encephalopathy (MHE)” which is characterized by cognition dysfunction 
without overt encephalopathy (24). There is no current consensus on how MHE should be 
diagnosis. However, there are the following several requirements to diagnosis of MHE; 1. Normal 
mental status on clinical examination. 2. Documentation of neurological impairment by the 
multiple methods. 3. Exclusion of other disturbance that may cause the neurological impairment 
(25). In this study, our patients have normal mental status and do not have other neurological 
impairment, but did not documented neurological impairment. Therefore, our patients could not 
diagnose to MHE. However, we think that an enough evaluation for the relation with MHE and 
sleep disturbance is necessary. Previous report described that the psychometric test were not 
correlated with ESS (26), there was no relationship between sleep and cognitive performance 
either at baseline or in relation to treatment (27). There is a positive correlation in HME and 
Child-Pugh score(25), but is no correlation in sleep disturbance and Child-Pugh score (1). In this 
study, ESS is not relation with liver function and cirrhotic symptom related score. It has been 
considered that MHE is a part of cause for sleep disturbance in cirrhotic patient, but we think that 
another inducer of sleep disturbance is existence.  
It is speculated by groups that think relationship between sleep disturbance and MHE that 
the mechanism of sleep disturbance in cirrhotic patient is the deterioration of circadian rhythm (1. 
24). Specially, melatonin and that metabolite, brain hormone, common pacemaker of circadian 
rhythm, are hepatic metabolism, and it caused sleep disturbance for delayed sleep phase that the 
melatonin levels of peak significantly delayed in cirrhotic patient (28). However, contrary, it is 
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reported that cirrhosis dose not shift the circadian phase of plasma fibrinolysis (29). Because we 
did not evaluate sleep phase in our cirrhotic patients, it is necessary to wait for the evaluation in 
the future about an abnormal circadian variation. However, we learnt that BCAA snack is 
effectiveness for sleep disturbance in cirrhotic patient. Tryptophan, aromatic amine acid, elevated 
in cirrhotic patient, is the precursor for the neurotransmitter 5-hydroxytryptamine (5-HT), which is 
involved in fatigue and sleep (30. 31). In previous report (31), it is suggested that BCAA 
supplementation may help to counteract the effects of an increase in plasma free tryptophan. It has 
been suggested that the plasma BCAA concentration may influence brain function and affect 
appetite, physical and mental fatigue, mental performance and physical endurance (32). In other 
report, it has been described that oral intake of BCAA may reduce tryptophan uptake and 5-HT 
synthesis and release, thereby delaying fatigue (30). Recently, it is reported that fatigue in liver 
disease is significant and associates with excessive daytime sleepiness and high average of ESS 
(6). In this study, ESS is not related with our indicated data, but it will be necessary to examine the 
participations of the factor, for instance, fatigue, other than having examined in this study.  
In our study, the difference of BTR with BCAA group and control group was not founded. 
We speculated that the cause is the short treatment period. In previous reports, the elevation of 
BTR was observed at 3 month (33) and 1 year (34) after BCAA supplementation group 
(Aminoleban EN). We think that elevation of BTR in BCAA group at 8 week might be caused by 
an increase in number of entry cases. 
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Since benzodiazepines should not be used for cirrhotic patients with sleep disturbance (35), 
availability of orally taken BCAA snack for cirrhotic patient with sleep disturbance will be 
necessary to verify. Previous report showed that BCAA can be a psychotropic drug which 
directly acts on the central nervous system (4). The restless legs syndrome and obstructive sleep 
apnea syndrome are known as the cause of sleep disturbance in cirrhotic patients (6. 36). The 
cause of sleep disturbance and the relationship with prognosis and sleep disturbance will be 
subjective of future research.  
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Figure legend 
Figure 1. The transition of cirrhotic symptom related score and ESS during the follow up 
period. 
Value of cirrhotic symptom related score (A) and ESS (C) at 4 weeks and 8 weeks. Change of 
cirrhotic symptom related score (B) and ESS (D). “4W-entry” is an increment value in which the 
data of pre-treatment is pulled from the data of 4 weeks after the observation beginning. “8W-entry” 
and “8W-4W” also were calculated the increment between two indicated period. Black box is the 
mean value in observation group. Gray box is the mean value in BCAA group. * is p<0.1. ** is 
p<0.05. *** is p<0.01.  
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Figure 2. The scatter graph of ESS, cirrhotic symptom related score and Child-Pugh score. 
The scatter graph is between cirrhotic symptom related score and ESS (A), cirrhotic symptom 
related score and Child-Pugh score (B), Child-Pugh score and ESS score (C) and increment of 
cirrhotic symptom related score from 8 weeks after to entry and increment of ESS from 8 weeks 
after to entry (D). The increment value calculated the difference from at 8 weeks after to at entry. 
Black circle indicated to the patient in observation group. Gray circle indicated to the patient in 
BCAA group. “R” is correlation coefficient. The relation between cirrhotic symptom related score 
and Child-Pugh score showed a positive correlation statistically.  
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Table 1. Clinical characteristics at entry. 
Character  BCAA group (n=12)  Control group (n=9) 
Disease   Viral 8: Alcoholic 2: other 2 Viral 6: Alcoholic 2: other 2 
Sex (Female: Male) 7: 5    4: 5 
Child-Pugh score 6.36±1.65    6.33±1.62 
BMI   25.6±5.61   23.8±3.86 
Age   66.2±8.21    67.4±9.86 
TP   7.29±0.65   6.63±0.804 
Alb   3.57±0.83   3.44±0.663 
WBC   2972±970   2851±940 
RBC   381±82.0   359±71.9 
Plt   7.01±2.02   9.28±3.86 
PT   65.1±15.7   75.3±21.7 
BUN   15.4±5.57   17.3±5.22 
Cr   0.745±0.112   0.869±0.186 
AST   45.1±22.7    47.0±19.3 
ALT   35.9±27.0   38.8±20.9 
ALP   431.4±217.7   344.8±150.6 
γ-GTP   74.0±99.1   69.3±68.2 
TB   1.57±0.735   1.01±0.704 
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BTR   3.35±1.78   3.50±1.53 
NH3   64.9±30.6   75.3±52.3 
ChE   176.2±115   150.2±66.4 
TC   159.4±30.7   137.1±35.4 
TG   63.0±33.2   74.3±23.4 
FPG   107.4.8±27.2   115.4±27.2 
CSS   17.4±8.1   16.7±10.1 
ESS   7.73±4.47   4.67±3.35 
Data are shown as means ± standard deviation and numbers, with statistical analysis using a 
Mann–Whitney test for means and χ-square test for number. Statistical significance difference 
between BCAA and control group is not detected in this table. 
Normal values in laboratory tests: ALT (IU/l), 5–40; AST (IU/l), 10–40; γ-GTP (IU/l), <70 in males, 
<30 in females; TP (g/dl), 6.7–8.3; ALB (g/dl), 4.0–5.0; WBC (/μl), 3500–9000; RBC (×104/μl), 
450–580 in males, 380–480 in females; Plt (×104/μl), 14–33; PT (%), 70-130 ; BUN (mg/dL), 
8.0-22.0; Cr (mg/dL), 0.61-1.04 in males, 0.47-0.79 in females; ALP (IU/l), 115-359; LDH (IU/l), 
119–229; TB (mg/dl), 0.3–1.5; BTR,5-9.5; NH3 (μg/dl), <75; ChE (IU/l), 214–466; TC (mg/dl), 
128–220; TG (mg/dl), 38–150; FPG (mg/dl), 70–110 
BMI; body weight (kg)/ height (m) / height (m) 
CSS; cirrhotic symptom related score 
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Table 2. Variation of laboratory data from at entry to 8 week. 
  at 8 weeks after the entry  8 week - entry 
Laboratory data BCAA  Control  BCAA  Control 
BMI  26.1±5.24  23.7±4.00  0.234±0.543 -0.097±0.827 
TP  7.18±0.656 6.66±0.835 -0.133±0.42 0.038±0.66 
Alb  3.52±0.67  3.43±0.732 -0.017±0.46 -0.013±0.20 
WBC  3391±91182 2900±1009 308.3±588 48±560 
RBC  385±77.6  353±70.9  6.01±36.6  -6.44±24.4 
Plt  7.39±2.44  10.26±5.07 -0.133±0.856 0.978±1.646 
PT  66.1±14.7  71.7±15.5  -4.43±27.4 -3.59±8.18 
BUN  14.8±4.37  18.3±5.99  -0.58±4.00 1.00±5.41 
Cr  0.77±0.112 0.89±0.209 0.23±0.053 0.23±0.063 
AST  44.5±15.73 45.0±16.2  -2.00±14.9 -1.50±23.8 
ALT  33.3±14.09 29.6±11.0  -2.58±25.0 -9.22±19.3 
ALP  412.4±180.1 358.9±150.1 -21.4±141 14.0±64.2 
γ-GTP  76.8±103.1 53.1±38.4  6.58±21.3  -16.2±37.2 
TB  1.33±0.799 0.80±0.654 -0.25±0.487 -0.21±0.262 
BTR  3.69±1.90  3.86±1.50  0.445±1.17 0.364±0.795 
NH3  72.6±31.64 63.9±34.0  8.63±21.2  -12.3±18.1 
ChE  175.0±94.3 147.7±74.6 2.42±42.4  -2.56±18.7 
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TC  147.5±30.0 127.6±28.7 -9.67±19.5 -9.56±18.3 
TG  52.0±18.2  58.7±42.7  -12.5±12.8 -7.00±23.3 
FPG  105.7±73.2 111.6±24.2 21.7±71.3  -45.6±77.6 
“8 week - entry” is an increment value in which the data of pre-treatment is pulled from the data of 
4 weeks after the observation beginning. Data are shown as means ± standard deviation and 
numbers, with statistical analysis using a Mann–Whitney test for means. Statistical significance 
difference between BCAA and control group is not detected in this table. Normal values in 
laboratory tests are same as table1.  
 
